Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 349 for:    paul read
Previous Study | Return to List | Next Study

Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02145286
Recruitment Status : Active, not recruiting
First Posted : May 22, 2014
Last Update Posted : June 12, 2018
Sponsor:
Information provided by (Responsible Party):
Paul W. Read, MD, University of Virginia

Brief Summary:
The purpose of this research study is to evaluate the safety and effectiveness of an experimental procedure called Focused Radiation that may result in a faster way to plan and deliver radiation for the treatment of pain caused by metastatic bone tumors (cancerous tumors that originally came from another organ and have spread to bones). In this trial a single fraction of radiation will be given from 8-15 Gray.

Condition or disease Intervention/treatment Phase
Metastatic Bone Lesion Radiation: Stereotactic Body Radiation Therapy Not Applicable

Detailed Description:

The purpose of this research study is to evaluate the safety and effectiveness of an experimental procedure called Focused Radiation that may result in a faster way to plan and deliver radiation for the treatment of pain caused by metastatic bone tumors (cancerous tumors that originally came from another organ and have spread to bones).

Focused radiation (the radiation is focused on the tumor in the bone with reduced radiation dose to the normal tissues) is used as standard of care treatment for patients with painful metastatic tumors in their spines with just one treatment. In this study, the focused radiation will be used to treat tumors in other bones as well. The current standard of care radiation treatment planning and delivery can take 2 to 3 weeks from start to finish depending on how many treatments are given although the standard of care is to treat patients with 1-10 treatments. The University of Virginia has developed an experimental workflow/process: a radiation treatment planning and delivery workflow called "STAT RAD" (STAT means "right away", and RAD means radiation). This experimental workflow will shorten the time it takes to plan and treat painful bone metastases to 1-2 hours.

When only one treatment is given the standard radiation dose is 8 Gray. This has resulted in radiation retreatment rates to the treated bone of 20% in prior studies for persistent or recurrent bone pain. In this study patients will be treated with higher doses of targeted radiation to determine if higher doses, which have been reported to be safely delivered for bone metastases in the spine with very low re-treatment rates, can be safely delivered to non-spine bone metastases. After the treatment, patients will be followed for pain relief in the treated bone, need for pain medication, quality of life, toxicity, and the need to retreat the bone metastasis for persistent or recurrent pain.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 47 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Single Arm Prospective Single Fraction Real-time Stereotactic Body Radiation Therapy Dose Escalation Trial of Rapid Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease
Study Start Date : October 2013
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Arm Intervention/treatment
Experimental: Radiation Therapy
Stereotactic Body Radiation Therapy
Radiation: Stereotactic Body Radiation Therapy
SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors




Primary Outcome Measures :
  1. Radiation Dose [ Time Frame: Up to 12 months following treatment ]
    Determine the optimal dose range for treatment of osseous bone metastases with single SBRT (Stereotactic Body Radiation Therapy) treatment using the STAT RAD (right away/radiation) workflow


Secondary Outcome Measures :
  1. Single Treatment Pain Scores [ Time Frame: Up to 4 weeks following treatment ]
    Patients will complete questionnaires to determine whether the treatment of osseous bone metastases with single treatment using the STAT RAD workflow results in a significant change in pain scores at 4 weeks following treatment of patients with good prognosis, compared to baseline scores

  2. Paired Dose Pain Score Comparison [ Time Frame: Up to 4 weeks following treatment ]
    Patient questionnaires will be used to estimate the difference in the mean change in pain score from baseline to 4 weeks following treatment of patients with good prognosis between pairs of dose levels among those in the range of optimal doses

  3. Post Treatment Measures [ Time Frame: Up to 12 months following treatment ]
    Patients will complete questionnaires to capture pain scores of the treated lesion(s), analgesic use, patient functional status, patient quality of life, and patient satisfaction at 1,4,8, and 12 weeks and at 6 and 12 months following treatment. Rates of radiation-retreatment within one year will also be captured for the treated target lesion(s).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has 1-3 major painful osseous metastases (target lesions)
  • Radiographic evidence (CT, MR, or PET CT) consistent with osseous metastatic disease on CT, MR, or PET CT obtained within 4 weeks of treatment will be used for pre-study treatment delivery. The GTV of the target lesions will be determined from this radiographic study and must be ≤ 250 cubic centimeters.

NOTE: Patient is still eligible if a diagnostic image set is not available within 4 weeks of treatment if the patient will undergo a kVCT simulation in the Department of Radiation Oncology with contouring directly onto this image set.

  • Patient is medically able to undergo palliative radiation therapy
  • Patient has pain that is persistent and distinguishably associated with the target sites to be treated
  • Planning Target Volume 1 (PTV1) must be > 5mm from the spinal cord or brain
  • Women of Childbearing age and men must consent to use adequate contraception for six months following study entry

Exclusion Criteria:

  • Inability to lie on the treatment table for 1 hour
  • Systemic therapeutic radionuclide delivery within 30 days prior to treatment
  • Target lesions have been previously treated with external beam radiation
  • Long bone target lesions with a Mirels fracture score >7
  • Unstable bone in the target lesion requiring surgical stabilization
  • PTV1 is located within 5mm of spinal cord or brain
  • A serious, uncontrolled medical disorder
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02145286


Locations
Layout table for location information
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Paul W. Read, MD
Investigators
Layout table for investigator information
Principal Investigator: Paul W Read, MD, PhD University of Virginia

Layout table for additonal information
Responsible Party: Paul W. Read, MD, Professor, University of Virginia
ClinicalTrials.gov Identifier: NCT02145286     History of Changes
Other Study ID Numbers: 16964
First Posted: May 22, 2014    Key Record Dates
Last Update Posted: June 12, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No